etidronate has been researched along with Groenblad-Strandberg Syndrome in 11 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect of the bisphosphonate etidronate on choroidal neovascular (CNV) activity in patients with pseudoxanthoma elasticum (PXE)." | 9.34 | The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum. ( de Jong, PA; Imhof, SM; Mali, WPTM; Ossewaarde-van Norel, J; Risseeuw, S; Spiering, W; van Leeuwen, R, 2020) |
| "In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)." | 9.27 | Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. ( Bartstra, JW; de Jong, PA; de Vries, JJ; den Harder, AM; Imhof, SM; Kranenburg, G; Lagerweij, SJ; Lam, MG; Luurtsema, G; Mali, WP; Ossewaarde-van Norel, J; Risseeuw, S; Slart, RHJA; Spiering, W; van Leeuwen, R; Verhaar, HJ; Visseren, FLJ, 2018) |
| "Etidronate treatment halts systemic arterial calcification in PXE." | 6.94 | Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. ( Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020) |
| "To assess the effect of the bisphosphonate etidronate on choroidal neovascular (CNV) activity in patients with pseudoxanthoma elasticum (PXE)." | 5.34 | The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum. ( de Jong, PA; Imhof, SM; Mali, WPTM; Ossewaarde-van Norel, J; Risseeuw, S; Spiering, W; van Leeuwen, R, 2020) |
| "In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)." | 5.27 | Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. ( Bartstra, JW; de Jong, PA; de Vries, JJ; den Harder, AM; Imhof, SM; Kranenburg, G; Lagerweij, SJ; Lam, MG; Luurtsema, G; Mali, WP; Ossewaarde-van Norel, J; Risseeuw, S; Slart, RHJA; Spiering, W; van Leeuwen, R; Verhaar, HJ; Visseren, FLJ, 2018) |
| "Etidronate treatment halts systemic arterial calcification in PXE." | 2.94 | Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. ( Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020) |
| "Pseudoxanthoma elasticum is a prototype of heritable ectopic mineralization disorders, with phenotypic overlap with generalized arterial calcification of infancy and arterial calcification due to CD73 deficiency." | 2.55 | Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. ( Li, Q; Terry, SF; Uitto, J; van de Wetering, K; Váradi, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kauffenstein, G | 1 |
| Chappard, D | 1 |
| Leftheriotis, G | 1 |
| Martin, L | 2 |
| Bartstra, JW | 2 |
| de Jong, PA | 3 |
| Kranenburg, G | 2 |
| Wolterink, JM | 1 |
| Isgum, I | 1 |
| Wijsman, A | 1 |
| Wolf, B | 1 |
| den Harder, AM | 2 |
| Mali, WPTM | 2 |
| Spiering, W | 3 |
| Risseeuw, S | 2 |
| van Leeuwen, R | 2 |
| Imhof, SM | 2 |
| Ossewaarde-van Norel, J | 2 |
| Stumpf, MJ | 1 |
| Schaefer, CA | 1 |
| Schahab, N | 1 |
| Uitto, J | 3 |
| Li, Q | 3 |
| van de Wetering, K | 2 |
| Váradi, A | 2 |
| Terry, SF | 2 |
| Pomozi, V | 1 |
| Brampton, C | 1 |
| Zoll, J | 1 |
| Calio, B | 1 |
| Pham, K | 1 |
| Owens, JB | 1 |
| Marh, J | 1 |
| Moisyadi, S | 1 |
| Bauer, C | 1 |
| Erdmann, J | 1 |
| Aherrahrou, Z | 1 |
| Le Saux, O | 1 |
| Lagerweij, SJ | 1 |
| Lam, MG | 1 |
| Verhaar, HJ | 1 |
| de Vries, JJ | 1 |
| Slart, RHJA | 1 |
| Luurtsema, G | 1 |
| Visseren, FLJ | 1 |
| Mali, WP | 1 |
| Apschner, A | 1 |
| Huitema, LF | 1 |
| Ponsioen, B | 1 |
| Peterson-Maduro, J | 1 |
| Schulte-Merker, S | 1 |
| Sundberg, JP | 1 |
| Levine, MA | 1 |
| Moore, SN | 1 |
| Tanner, SB | 1 |
| Schoenecker, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)[NCT03813550] | 20 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)[NCT04660461] | Phase 4 | 20 participants (Anticipated) | Interventional | 2020-02-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for etidronate and Groenblad-Strandberg Syndrome
| Article | Year |
|---|---|
Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Animals; Biopsy, Needle; Clinical Trials as Topic; Congresses | 2017 |
3 trials available for etidronate and Groenblad-Strandberg Syndrome
| Article | Year |
|---|---|
Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum.
Topics: Aged; Arteries; Etidronic Acid; Female; Humans; Male; Middle Aged; Pseudoxanthoma Elasticum; Single- | 2020 |
The effect of etidronate on choroidal neovascular activity in patients with pseudoxanthoma elasticum.
Topics: Aged; Choroidal Neovascularization; Double-Blind Method; Drug Administration Schedule; Etidronic Aci | 2020 |
Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Calcium; Drug Monitoring; Etidronic Acid; Fema | 2018 |
7 other studies available for etidronate and Groenblad-Strandberg Syndrome
| Article | Year |
|---|---|
ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?
Topics: Bone Diseases, Metabolic; Etidronic Acid; Humans; Multidrug Resistance-Associated Proteins; Mutation | 2022 |
From osteoporosis to pseudoxanthoma elasticum - etidronate in a vascular disease.
Topics: Etidronic Acid; Humans; Osteoporosis; Pseudoxanthoma Elasticum; Vascular Calcification; Vascular Dis | 2020 |
Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.
Topics: Acute Disease; Animals; ATP-Binding Cassette Transporters; Calcinosis; Chronic Disease; Diphosphates | 2017 |
Vascular Mineralization in Pseudoxanthoma Elasticum: Etidronate to the Rescue?
Topics: Etidronic Acid; Humans; Pseudoxanthoma Elasticum; Vascular Calcification | 2018 |
Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE).
Topics: Animals; Biomarkers; Calcinosis; Calcium; Choristoma; Etidronic Acid; Fibroblast Growth Factor-23; H | 2014 |
The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Drug Eval | 2015 |
Bisphosphonates: from softening water to treating PXE.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Etidronic | 2015 |